Growing controversy over role of FDA and Medicare in promoting anti-amyloid drugs given limited benefit, high cost, severe side-effects

By SharpBrains | June 21, 2023

The War Over Whether Medicare Should Pay For The New Anti-Alzheimer’s Drugs (Forbes): The pow­er­ful Alzheimer’s Dis­ease lob­by is fight­ing a mul­ti-bil­lion-dol­lar bat­tle on two fronts. It is qui­et­ly try­ing to lim­it restric­tions the Food and Drug Admin­is­tra­tion puts on the use of new drugs aimed at slow­ing the pro­gres­sion of the brain dis­ease. And…

Read More

Latest brain research, tools and teasers to think outside the mental health status quo box

By SharpBrains | February 26, 2020

__ Time for a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing a range of  research find­ings, resources, brain teasers and rid­dles to help trans­late emerg­ing neu­ro­science into real-world appli­ca­tions and improve our col­lec­tive brain & men­tal health. New think­ing: Neu­ro­science tips about grat­i­tude, aging, pain and the brain: An inter­view with Dr. Daniel Lev­itin What’s normal?…

Read More

June 22nd talk @ Fundacion Edad y Vida (Barcelona) on Health in the XXI century

By Alvaro Fernandez | June 9, 2010

Last Novem­ber, talk­ing with some Japan­ese col­leagues at the World Eco­nom­ic Forum’s Coun­cil on the Aging Soci­ety, I dis­cov­ered that it is com­mon there to orga­nize research-dri­ven consortia/ learn­ing labs among for-prof­it, non-prof­it and aca­d­e­m­ic orga­ni­za­tions inter­est­ed in the devel­op­ment of “sil­ver indus­tries”, this is, where com­pa­nies devel­op prod­uct and ser­vices spe­cif­ic to the needs…

Read More